WINNERS & LOSERS: Camellia slumps on macadamia woe; Record climbs
22nd Oct 2026 11:13
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday. Read More
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday. Read More
(Alliance News) - The UK government has hit back after Donald Trump's lead negotiator on the Ukraine war described Russian President Vladimir Putin as a "humanitarian". Read More
(Alliance News) - Inchcape PLC on Thursday lowered its earnings and margin guidance for 2026 to reflect a "challenging situation in Australia", which overshadowed volume growth elsewhere. Read More
(Alliance News) - AstraZeneca PLC on Thursday said subsidiary Alexion Pharmaceutical's Ultomiris has received accelerated approval in the US for the treatment of a rare kidney disease called immunoglobulin A nephropathy. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Thursday. Read More
(Alliance News) - IG Group Holdings PLC on Thursday reaffirmed its annual and medium-term guidance despite reporting a double-digit-percentage fall in third-quarter revenue, as the trading platform operator outlined plans to expand into prediction markets and broaden its product offering. Read More
(Alliance News) - Pearson PLC on Thursday said it was restructuring its business into four divisions as it reported revenue growth accelerated in the third quarter. Read More
(Alliance News) - J Sainsbury PLC on Thursday lifted its profit outlook as it reported "volume growth, share gains and profit growth" in its half-year, but shares struggled as its second quarter sales rose at a softer pace than expected. Read More
AstraZeneca PLC - Cambridge, England-based pharmaceutical company - Says its Ultomiris drug has received accelerated approval from the US Food & Drug Administration to reduce proteinuria, or excess protein in urine, in adults with primary immunoglobulin A nephropathy, a rare inflammatory kidney disease, who are at risk of disease progression. Ultomiris becomes the first and only C5 complement inhibitor approved in the US for this indication. Approval follows interim results from the phase III I CAN trial, which showed a 43.4% reduction in proteinuria compared with placebo after 34 weeks. AstraZeneca says the trial remains ongoing to assess whether Ultomiris can slow kidney function decline, with continued approval potentially dependent on confirmation of clinical benefit. The approval marks the fifth indication for Ultomiris. Read More
(Alliance News) - Barclays PLC has revealed it expects to have cut around 5,000 staff by the end of 2026 after turning to artificial intelligence (AI) to make the bank more efficient. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday: Read More
(Alliance News) - Relx PLC on Thursday reported revenue growth in the first nine months of 2026, supported by demand for AI-enabled analytics and decision tools and reaffirmed its full-year outlook. Read More
(Alliance News) - The security of next week's government Budget has not been compromised by a critical security flaw in a programming language used by the majority of websites, a minister has said. Read More
(Alliance News) - InterContinental Hotels Group PLC on Thursday said revenue per available room accelerated in the third quarter despite a slowdown in China. Read More
(Alliance News) - Anglo American PLC on Thursday said it has promoted Non-Executive Director Anne Wade to senior independent director, starting immediately and replacing Ian Tyler. Read More